Cardiol Therapeutics Inc. (TSE:CRDL - Get Free Report) fell 7.7% during trading on Friday . The stock traded as low as C$1.88 and last traded at C$1.91. 75,056 shares were traded during mid-day trading, an increase of 45% from the average session volume of 51,603 shares. The stock had previously closed at C$2.07.
Cardiol Therapeutics Stock Performance
The business's 50 day simple moving average is C$1.93 and its two-hundred day simple moving average is C$2.42. The company has a current ratio of 2.39, a quick ratio of 6.84 and a debt-to-equity ratio of 1.07. The firm has a market capitalization of C$132.07 million, a PE ratio of -4.30 and a beta of 0.70.
Insider Buying and Selling at Cardiol Therapeutics
In related news, Senior Officer Andrew Warwick Hamer purchased 18,900 shares of Cardiol Therapeutics stock in a transaction on Thursday, December 19th. The shares were bought at an average cost of C$1.88 per share, for a total transaction of C$35,606.69. Also, Director David Elsley purchased 40,000 shares of the firm's stock in a transaction on Monday, December 16th. The stock was bought at an average price of C$1.88 per share, for a total transaction of C$75,072.00. Over the last ninety days, insiders acquired 86,140 shares of company stock valued at $161,456. Insiders own 4.57% of the company's stock.
About Cardiol Therapeutics
(
Get Free Report)
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Read More
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
